The 36-month beta value for AQST is at 1.93. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AQST is 91.68M, and currently, shorts hold a 10.73% of that float. The average trading volume for AQST on June 04, 2025 was 1.43M shares.
AQST) stock’s latest price update
Aquestive Therapeutics Inc (NASDAQ: AQST)’s stock price has increased by 13.17 compared to its previous closing price of 2.81. However, the company has seen a 24.71% increase in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-13 that Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb – IR Dan Barber – CEO Ernie Toth – CFO Sherry Korczynski – SVP of Sales and Marketing Carl Kraus – CMO Conference Call Participants Roanna Ruiz – Leerink Partners David Amsellem – Piper Stanley Kristen Kluska – Cantor Fitzgerald Jason Butler – Citizens JMP Raghuram Selvaraju – HC Wainwright Dennis Resnick – Raymond James Nelson Cox – Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Aquestive Therapeutics First Quarter 2025 Earnings Conference Call.
AQST’s Market Performance
AQST’s stock has risen by 24.71% in the past week, with a monthly rise of 6.00% and a quarterly rise of 16.48%. The volatility ratio for the week is 6.35% while the volatility levels for the last 30 days are 6.90% for Aquestive Therapeutics Inc The simple moving average for the last 20 days is 23.23% for AQST stock, with a simple moving average of -14.23% for the last 200 days.
Analysts’ Opinion of AQST
Many brokerage firms have already submitted their reports for AQST stocks, with Oppenheimer repeating the rating for AQST by listing it as a “Outperform.” The predicted price for AQST in the upcoming period, according to Oppenheimer is $7 based on the research report published on June 02, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see AQST reach a price target of $17. The rating they have provided for AQST stocks is “Overweight” according to the report published on December 17th, 2024.
Leerink Partners gave a rating of “Outperform” to AQST, setting the target price at $8 in the report published on May 10th of the previous year.
AQST Trading at 17.20% from the 50-Day Moving Average
After a stumble in the market that brought AQST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.17% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AQST starting from Jung Cassie, who sale 44 shares at the price of $4.87 back on Nov 26 ’24. After this action, Jung Cassie now owns 0 shares of Aquestive Therapeutics Inc, valued at $214 using the latest closing price.
Stock Fundamentals for AQST
Current profitability levels for the company are sitting at:
- -0.76 for the present operating margin
- 0.68 for the gross margin
The net margin for Aquestive Therapeutics Inc stands at -1.0. The total capital return value is set at -0.49.
Based on Aquestive Therapeutics Inc (AQST), the company’s capital structure generated -1.8 points at debt to capital in total, while cash flow to debt ratio is standing at -1.25. The debt to equity ratio resting at -0.64. The interest coverage ratio of the stock is -2.44.
Currently, EBITDA for the company is -26.62 million with net debt to EBITDA at 0.84. When we switch over and look at the enterprise to sales, we see a ratio of 5.28. The receivables turnover for the company is 5.19for trailing twelve months and the total asset turnover is 0.53. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.87.
Conclusion
In conclusion, Aquestive Therapeutics Inc (AQST) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
